| Stefanie Russell, MD | |
|
580 Court St, Keene, NH 03431-1718 | |
| (603) 354-5400 | |
| Not Available |
| Full Name | Stefanie Russell |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 6 Years |
| Location | 580 Court St, Keene, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073019030 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna At Hcs Inc | Keene, NH | Home health agency |
| Cheshire Medical Center | Keene, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cheshire Medical Center | 1456260165 | 155 |
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.
Schizophrenia patients, their families, and psychiatrists differ significantly in their perception of remission, study results show.
› Verified 3 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.
Schizophrenia patients, their families, and psychiatrists differ significantly in their perception of remission, study results show.
› Verified 3 days ago
| Entity Name | Cheshire Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093803397 PECOS PAC ID: 1456260165 Enrollment ID: O20070913000090 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.
Schizophrenia patients, their families, and psychiatrists differ significantly in their perception of remission, study results show.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stefanie Russell, MD Po Box 810, Hanover, NH 03755-0810 Ph: (603) 308-1467 | Stefanie Russell, MD 580 Court St, Keene, NH 03431-1718 Ph: (603) 354-5400 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.
Schizophrenia patients, their families, and psychiatrists differ significantly in their perception of remission, study results show.
› Verified 3 days ago
Dr. Leslie Thomas Pitts, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 Court St, Keene, NH 03431 Phone: 603-354-5454 Fax: 603-354-6552 | |
Claire M. Naylor, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 590 Court St, Keene, NH 03431 Phone: 603-354-5454 | |
David Bruce Richardson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 69 Island St Ste C, Keene, NH 03431 Phone: 603-654-6700 Fax: 603-354-6704 | |
Sharon E. Ferguson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 Court St, Keene, NH 03431 Phone: 603-354-5400 | |
Eric J Canzanello, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 Court St, Dartmouth-hitchcock Clinic - Family Medicine, Keene, NH 03431 Phone: 603-354-5400 | |
Dr. Karoline L Kimball, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 Court St, Keene, NH 03431 Phone: 603-354-5454 |